Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with a lead focus on locally advanced pancreatic cancer. The news flow around Silexion centers on its progress with SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes that drive aggressive solid tumors.
Readers following SLXN news can expect updates on preclinical data, regulatory milestones, and clinical trial preparations. Recent press releases have highlighted new human cancer cell line results demonstrating high inhibition across multiple KRAS mutations and organ sites, including pancreatic, colorectal, lung, and gastric cancer models. The company has also reported biodistribution and efficacy data in metastatic pancreatic cancer models, as well as completion of two-species toxicology studies that it states confirmed no systemic organ toxicity.
Another key theme in Silexion’s news is its regulatory and clinical development pathway for SIL204. The company has announced formal written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on the design of its planned Phase 2/3 trial in locally advanced pancreatic cancer, submission of a clinical trial application in Israel, and plans for additional submissions in Europe and the United States. Operational updates include selection of a contract research organization, manufacturing collaborations, and preparations for trial initiation.
In addition, Silexion’s news releases cover financing transactions, capital-raising activities, and Nasdaq listing matters, such as regaining compliance with minimum bid price and shareholders’ equity requirements. Investors and observers can use this news page to review company communications on scientific results, regulatory interactions, business developments, and conference presentations related to Silexion’s KRAS-focused RNAi oncology programs.
Silexion Therapeutics (NASDAQ: SLXN) has dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. Treatment began at Tel Aviv Sourasky Medical Center in Israel.
The multinational, randomized, open-label study, in which treatment assignments are known, compares SIL204 plus standard chemotherapy with chemotherapy alone. An initial safety cohort of approximately 18 patients precedes a randomized cohort of approximately 166 patients. Treatment combines ultrasound-guided injections directly into the pancreatic tumor with injections under the abdominal skin.
The Israeli center received institutional ethics approval and Ministry of Health authorization. Additional Israeli and German sites are progressing through activation; Silexion expects them to join in the coming months and is working toward preliminary clinical readouts in the near term.
Silexion Therapeutics (SLXN) signed agreements for the immediate exercise of Series E warrants covering up to 3,216,928 ordinary shares.
The exercise price was reduced to $0.2603 per share. Gross proceeds are expected to be $837,366.36 before placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026. In exchange for the cash exercise, Silexion will issue Series F and Series G warrants, each covering up to 3,216,928 shares at $0.2603 per share. The new warrants become exercisable after an increase in authorized ordinary shares takes effect following shareholder approval. Silexion also reduced the exercise price to $0.2603 for all outstanding Series E warrants covering 3,846,161 shares, including those covered by the exercise agreements.
Silexion Therapeutics (SLXN) reported preclinical SIL204 results showing dose-dependent KRAS gene silencing in human cancer cells. In a carrier-free assay without synthetic delivery reagents, SIL204 entered KRAS-driven cells in the presence of normal serum lipids. Removing those lipids reduced gene silencing (P < 0.001), while adding human low-density lipoprotein (LDL) to complete serum did not change potency. The cell-based findings link SIL204 uptake to naturally occurring lipids.
Silexion says the results support its plan to explore systemic subcutaneous delivery for disease beyond the primary tumor. Its Phase 2/3 program in locally advanced pancreatic cancer targets the primary tumor. Further studies of drug exposure, cellular uptake and tissue distribution are underway. The company is continuing trial-site initiation at Tel Aviv Sourasky Medical Center and patient screening, alongside regulatory clearances in Germany.
Silexion Therapeutics (SLXN) will participate in three industry and investor conferences in September 2026 to present its oncology programs and meet investors.
The company will present at the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9, 2026 and the 8th Annual RAS-Targeted Drug Development Summit on September 10, 2026, both in Boston, led by Chief Scientific and Development Officer Dr. Mitchell Shirvan. From September 14–16, 2026, Silexion will hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York with its CEO and CFO attending.
Silexion is developing SIL204, an investigational pan-KRAS RNA interference therapy in an ongoing Phase 2/3 program for locally advanced pancreatic cancer.
Silexion Therapeutics (NASDAQ: SLXN) reported second-quarter 2026 results and a major business transition as lead candidate SIL204 moved into an active Phase 2/3 trial in locally advanced pancreatic cancer. Clinical trial authorizations were obtained in Israel and Germany, and the first site at Tel Aviv Sourasky Medical Center was initiated on July 29, 2026, with patient screening cleared to begin.
The company expanded SIL204’s immuno-oncology profile with preclinical data showing immune-sensitization across three pathways and four KRAS mutations. To support the program and Nasdaq listing requirements, Silexion executed multiple capital actions, including a 1-for-10 reverse share split and an August 13, 2026 public offering raising approximately $2.5 million in gross proceeds. For Q2 2026, R&D expenses rose 120% year over year to about $2.2 million, G&A expenses increased 15.4% to about $1.5 million, and net loss widened to about $3.6 million. As of June 30, 2026, cash and cash equivalents were approximately $2.2 million, and reported shareholders’ equity was $44,000, while Silexion estimates adjusted shareholders’ equity of about $3.2 million after subsequent financing transactions, above Nasdaq’s minimum equity requirement.
Silexion Therapeutics (NASDAQ: SLXN) priced a public offering of 3,846,161 ordinary shares (or equivalents) and accompanying Series E warrants to purchase up to 3,846,161 ordinary shares at a combined public offering price of $0.65 per share and warrant.
The Series E warrants have a $0.65 exercise price, are immediately exercisable, and expire five years from issuance. Gross proceeds are expected to be approximately $2.5 million, before fees and expenses, with closing anticipated on or about August 13, 2026. According to Silexion Therapeutics, net proceeds will fund advancement of its SIL204 Phase 2/3 clinical trial and general corporate purposes. H.C. Wainwright & Co. is acting as exclusive placement agent under an effective Form S‑1 registration statement.
Silexion Therapeutics (NASDAQ: SLXN) reported new positive preclinical data showing that its KRAS-targeting siRNA SIL204 exerts multi-mechanism immune sensitization in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. SIL204 significantly upregulated the FAS (CD95) immune death receptor and downregulated HLA-G, an immune checkpoint, across KRAS G12D, G12V and G12C models.
Combined with previously reported MHC-I (HLA-ABC) upregulation in KRAS G12R-mutant pancreatic cells, the data support a coordinated signature involving increased antigen presentation, restored susceptibility to immune-mediated apoptosis, and reduced immune checkpoint activity across four KRAS mutations. According to Silexion, these findings reinforce the rationale for combining SIL204 with anti-PD-(L)1 therapies and provide additional translational support as SIL204 advances into Phase 2/3 clinical evaluation, following initiation of the first trial site at Tel Aviv Sourasky Medical Center in July 2026.
Silexion Therapeutics (NASDAQ: SLXN) has initiated its Phase 2/3 clinical trial of SIL204, its lead siRNA candidate, at Tel Aviv Sourasky Medical Center, formally activating the first site for patients with locally advanced pancreatic cancer. The site is now cleared to begin patient screening, with first dosing expected in the coming weeks.
According to Silexion, this milestone follows a rapid sequence of approvals and preparations in Israel and Germany, including Israeli Ministry of Health and BfArM authorizations, institutional ethics clearance, and GMP clinical supply manufacturing. The trial will start with a safety run-in of about 18 patients, then expand globally to a randomized cohort of roughly 166 patients, testing SIL204 plus standard chemotherapy via dual intratumoral and systemic administration.
Silexion Therapeutics (NASDAQ: SLXN) received unconditional approval from Germany's BfArM, with a positive ethics opinion, to start a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer. Alongside prior Israeli authorization, this clears initiation across both countries, with first patient dosing expected in the coming weeks.
The study will test SIL204 plus standard chemotherapy using dual intratumoral and systemic administration, beginning with ~18-patient safety run-in, then ~166-patient randomized expansion, and may later expand to additional EU states under the CTIS framework.
Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech developing RNAi therapies for KRAS-driven cancers, will attend the 2026 BIO International Convention in San Diego, CA from June 22–25, 2026.
Company leadership will host one-on-one investor and partner meetings during the convention.